BlueRock Therapeutics

BlueRock Therapeutics is a clinical stage cell therapy company dedicated to transforming the treatment of degenerative diseases by developing innovative cell therapy solutions. With a focus on neurology and ophthalmology, BlueRock aims to replace damaged or lost cells to create next-generation medicines with lasting impact. The company is currently working on investigational therapies such as bemdaneprocel for Parkinson’s disease and OpCT-001 for primary photoreceptor diseases, with several clinical trials underway.